Birt Hogg Dube Syndrome
     
  Search  
     
      Login
     
  Conference  
     
 

INAUGURAL BHD SYMPOSIUM

We are pleased to announce that the first Birt-Hogg-Dubé Symposium will be held in Roskilde, Denmark, on September 3, 2008. We look forward to the opportunity for those interested in BHD to meet in sessions that will present research and clinical aspects of the syndrome.

Roskilde is located on a beautiful fjord approximately one hour west of Copenhagen and is accessible by public transportation, rental car or taxi. It is a city with a rich cultural history that goes back to 998; it was the original capitol of the country. Vikings sailed the fjord and the Viking Ship Museum houses five original Viking ships. Roskilde Cathedral is a UNESCO World Heritage site and the burial place of Danish royalty. The city has many walking streets with shops and boutiques.

This BHD Symposium will be held the day before the VHL Symposium 2008. Both meetings will be held at the Comwell Conference Center, which overlooks the fjord. Roskilde was chosen as the conference site due to the affordability and accessibility of the conference site and housing,

Accommodation for the night of Sept. 2 is at the Scandic Roskilde, while from Sept. 3 there are rooms available at the Comwell conference center.

The BHD Family Alliance and the Myrovlytis Trust are helping to organize the Symposium.

Please email conference@bhdsyndrome.org with any questions.

Symposium Agenda

Morning: Molecular

09:35: Registration, 5 min intro

09:40 - 10:55: 5 * 15 min presentations (Chair - Laura Schmidt):

  • 09:40: Inactivation of the BHD gene in mice results in early embryonic lethality: the expression pattern and role of BHD in mouse embryo development. Speaker - Yukiko Hasumi.

  • 09:55: Role of the Birt-Hogg-Dubé Tumor Suppressor in Embryonic Development. Speaker - Tim Cash

  • 10:10: Functional Characterization of the BHD Tumor Suppressor Protein. Speaker - Arnim Pause

  • 10:25: FNIP1 inactivation in vivo leads to B-cell developmental defects: phenotypic analysis of a FNIP1 knockout mouse model. Speaker - Masaya Baba

  • 10:40: Identification and characterization of a novel folliculin-interacting protein FNIP2. Speaker - Hisashi Hasumi

10:55-11:25: Coffee

11:25 - 12:00: Keynote presentation - Dr Laura Schmidt. (Chair - Jorge Toro)

12:00 - 12:45: 3 * 15 min presentations (Chair - Jorge Toro)

  • 12:00: Interaction of folliculin (Birt-Hogg-Dube gene product) with a novel Fnip1-Like (FnipL) protein. Speaker - Yumiko Takagi

  • 12:15: Restoration of FLCN suppresses tumorigenic potential of a BHD patient-derived renal cancer cell line: Identification of the genes and signaling pathways affected by FLCN expression. Speaker - Laura Schmidt

  • 12:30: Folliculin-dependent regulation of HIF2-alpha . Speaker - Maurice van Steensel

12:45-14:10: Lunch and posters

Afternoon: Clinical

14:10-14:45: Keynote presentation - Dr Marston Linehan (Chair - Maurice van Steensel)

14:45 - 15:45: 4 * 15 min presentations (Chair - Maurice van Steensel)

  • 14:45: Mutation analysis of the Birt-Hogg-Dubé gene in patients with multiple lung cysts. Speaker - Makiko Kunogi

  • 15:00: Analysis of the BHD gene in a series of European patients suspected of Birt-Hogg-Dubé syndrome. Speaker - Sophie Giraud

  • 15:15: Dermatologic Investigations of Birt-Hogg-Dubé Syndrome at the National Cancer Institute. Speaker - Jorge Toro

  • 15:30: High-Resolution CT findings of the chest in 12 patients of Birt-Hogg-Dube syndrome. Speaker - Kazunori Tobino

15:45 - 16:15: Coffee

16:15-17:30: Patient Data and Treatment (Chair - Fred Menko):

  • 16:15: European BHD Consortium patient data. Speaker - Eamonn Maher

  • 16:30: Provisional Diagnostic Criteria, Genetic Testing and Recommendations for Screening and Surveillance Patients with Birt-Hogg-Dubé Syndrome. Speaker - Jorge Toro

  • 16:45: Panel discussion - treatment, future etc.

17:30: Finish

Information in English, with links to information in Danish

 
     
Print this page Email this page  
  Copyright © 2008 Myrovlytis Trust. All rights reserved Privacy policy Disclaimer  
Neither the Myrovlytis Trust, nor this website, provides medical advice, diagnosis or treatment. Click here for more information